Project Grant R01AI188950
Award Date
12/6/24
Completion Date
11/30/29
Dollars Obligated
$755K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Maywood, IL 60153, USA
Similar Awards
This $15,981,588 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases aims to develop pan-coronavirus vaccines. Led by Washington University, the collaborative program includes eleven laboratories seeking to design optimized B and T cell antigens conferring broad immunity against sarbecoviruses and merbecoviruses. The three-year award beginning September 2022 supports three integrated research projects and two centralized cores. Project 1...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...
This three-year, $18.13 million project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at the University of Washington and five sub-awardee institutions to develop broadly protective coronavirus vaccines. Under the Allergy and Infectious Diseases Research program, the grantee and sub-awardees will pursue three outputs: tools to study coronaviruses, antibodies for treatment, and vaccine candidates. They will generate reverse...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,178,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The grant, which runs from August 20, 2024 to July 31, 2025, is for developing a "tunable nanophage platform" to rapidly screen and formulate multi-antigen vaccine candidates against emerging infectious disease threats like SARS-CoV-2 variants and pre-emergent SARS-like...
This federal Project Grant award of $781,718 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of a novel T cell-based vaccine to prevent Dengue virus (DENV) and Zika virus (ZIKV) infection. The research team at Loyola University of Chicago's Health Sciences Campus will design a vaccine that targets the ZIKV non-structural protein 3 (NS3) without the precursor membrane (PrM) and envelope (E)...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $705,557 to Emory University from December 20, 2024 to November 30, 2029. The project aims to advance understanding of the coordinated innate and cellular mucosal immune responses that contribute to SARS-CoV-2 viral clearance, particularly in the upper respiratory tract. Key objectives include determining the role of...
This Cooperative Agreement award for $2,380,350 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research at Washington University to study the mechanisms of broadly protective immune responses against respiratory viruses, including SARS-CoV-2 and influenza. The two main goals are: (A) defining the mechanisms of germinal center persistence after vaccination and how that impacts long-lived...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $668,569.00 to characterize and optimize a novel genetic vaccine platform called PARVAX. The key objectives are to: Investigate the mechanism behind the potency and durability of the PARVAX platform, hypothesized to be correlated with antigen expression kinetics. Use rational engineering approaches to enhance...
This Cooperative Agreement award of $41,075,241, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a highly synergistic center focused on developing end-to-end strategies for pandemic preparedness vaccine development targeting Bunyaviruses and Paramyxoviruses. The center brings together five research institutions with expertise in computational protein design, structure-based vaccine...
This $5.25 million project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at The Wistar Institute of Anatomy and Biology to develop a universal coronavirus vaccine utilizing nucleic acid delivered nanoparticles. The grant period runs from September 2022 through August 2025. Under the award, Wistar Institute researchers will manipulate variables such as antigen epitope diversity, density, valency, duration of antigen...